Entia Biosciences, Inc.
ERGO
Rank in Stocks
#34193
Entia Biosciences, Inc. engages in the development, production, and... Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
Share Price
$0.001
Last synced: 2026-11-09
Market Cap
$28.15K
Change (1 day)
0.00%
Change (1 year)
900.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Entia Biosciences, Inc. (ERGO)
Category
Healthcare
Operating Margin for Entia Biosciences, Inc. (ERGO)
Operating Margin as of November 2026 TTM: -439.75%
According to Entia Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -439.75%. At the end of 2016 the company had an operating margin of -439.75%.
Operating Margin history for Entia Biosciences, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -439.75% | 0.00% |
| 2016 | -439.75% | -20.38% |
| 2015 | -552.29% | 104.69% |
| 2014 | -269.82% | -68.33% |
| 2013 | -851.98% | 191.13% |
| 2012 | -292.65% | -19.89% |
| 2011 | -365.32% | 38.02% |
| 2010 | -264.69% | -74.39% |
| 2009 | -1,033.69% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | -100.14% |
US
|
|
| 31.60% | -100.07% |
SE
|
|
| 30.13% | -100.07% |
FR
|
|
| 29.76% | -100.07% |
HK
|
|
| 30.46% | -100.07% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Entia Biosciences, Inc.'s operating margin
What is Entia Biosciences, Inc.'s operating margin?
Entia Biosciences, Inc.'s operating margin is -439.75%, as of Nov 2026.
What was Entia Biosciences, Inc.'s operating margin in 2016?
In 2016, Entia Biosciences, Inc.'s operating margin was -439.75%, compared with -552.29% in 2015.
How has Entia Biosciences, Inc.'s operating margin changed since 2011?
From 2011 to 2016, Entia Biosciences, Inc.'s operating margin was highest in 2014 (-269.82%) and lowest in 2013 (-851.98%).
How does Entia Biosciences, Inc.'s operating margin compare with similar companies?
Entia Biosciences, Inc.'s operating margin (-439.75%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 62.34%.